Effect of High-dose Toremifene for premenopausal metastatic breast cancer
Phase 2
Recruiting
- Conditions
- premenopausal metastatic breast cancer
- Registration Number
- JPRN-UMIN000002867
- Lead Sponsor
- Multi Hormone Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
Patients have an inadequte organ function. Patients who have had any previous or concomitant malignancy. Patients who have had any other non-malignant systemic diseases (cardiovascular, renal lung, etc. ) that would prevent follow-up
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Benefit
- Secondary Outcome Measures
Name Time Method clinical response rate Time to progression Time to treatment failure adverse events